New Anti-Clotting Medication Shows Promise in Preventing Recurrent Strokes Without Bleeding Risk

An investigational anti-clotting medication called asundexian reduced the risk of a second ischemic stroke by 26% without increasing bleeding concerns when added to standard antiplatelet therapy, according to preliminary findings presented at the American Stroke Association’s International Stroke Conference 2026. The OCEANIC-STROKE study represents the first completed trial of a Factor XI inhibitor investigating whether this new class of medication can safely prevent recurrent strokes better than current standard treatments.

Nearly one in four stroke survivors will experience another stroke, according to the American Stroke Association, a division of the American Heart Association. Current guidelines recommend antithrombotic therapy for nearly all stroke survivors, but existing treatments have limitations. ‘Antiplatelet therapy has limited effectiveness in preventing recurrent stroke because of bleeding risks,’ said study principal investigator Mike Sharma, M.D., M.Sc., who noted that previous efforts to improve outcomes by adding other blood-thinning medications have failed due to increased bleeding risk or lack of benefit.

Asundexian works differently from existing anticoagulants by inhibiting a clotting protein called Factor XI. People born with a genetic deficiency of this protein are known to have lower stroke risk without experiencing spontaneous bleeding. The Phase III international trial included 12,327 stroke survivors who had experienced mild to moderate ischemic strokes not caused by heart conditions. Participants were randomly assigned to receive either standard antiplatelet therapy plus daily asundexian or standard therapy plus a placebo, with neither patients nor researchers aware of treatment assignments during the trial.

During follow-up periods ranging from 3 to 31 months, researchers found that adding asundexian to antiplatelet medication reduced ischemic stroke occurrence by 26% consistently across all participant groups regardless of age, sex, stroke cause, or initial stroke severity. The treatment also reduced disabling strokes and lowered cardiovascular death, stroke of any type, heart attack, and major bleeding collectively. Importantly, the medication did not increase bleeding within the brain or major bleeding and did not increase serious adverse effects.

‘Asundexian holds the potential to reduce the risk of a recurrent stroke over the long term without an increased safety risk,’ said Sharma, who serves as director of the Brain Health and Stroke program at the Population Health Research Institute. ‘If approved by the FDA, asundexian could be widely used for patients who have had a non-cardioembolic stroke or a TIA.’ The study was conducted at 702 sites in 37 countries between January 2023 and February 2025, with participants enrolled within 72 hours of their initial stroke or transient ischemic attack.

The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal. Asundexian remains an investigational medication that has not been approved in any country, though the U.S. Food and Drug Administration has granted it fast-track designation for potential use in stroke prevention. Additional information about stroke prevention and statistics is available through resources like the American Stroke Association’s health information at https://www.stroke.org and their guidelines at https://professional.heart.org/en/guidelines-and-statements.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is New Anti-Clotting Medication Shows Promise in Preventing Recurrent Strokes Without Bleeding Risk.

The post New Anti-Clotting Medication Shows Promise in Preventing Recurrent Strokes Without Bleeding Risk appeared first on citybuzz.